TDP-43 proteinopathy

• AC Immune

  Company1 trialEarly phase 145 people

National Institute on AgingUS$4.6mNational Institute of Neurological Disorders and StrokeUS$760.1k

• Defining short RNA therapeutics that combat TDP-43 proteinopathy connected to AD and ADRDs.

  National Institute on AgingUniversity of PennsylvaniaUS$3.4m2025–2029

• Disease Mechanism and Therapy in TDP-43 Proteinopathies and Dementias

  National Institute of Neurological Disorders and StrokeUniversity of California, San DiegoUS$760.1k1989–2027

• Biochemical and molecular heterogeneity of human TDP-43 proteinopathies in age-related dementias

  National Institute on AgingUniversity of PennsylvaniaUS$510.8k2022–2027

• Environmental risk factors linked to TDP-43 proteinopathies

  National Institute on AgingUniv of North Carolina Chapel HillUS$734.6k2024–2029